Novel anti-hepatitis B agents: A focus on telbivudine.

Article Details

Citation
Copy to clipboard

Jones R, Nelson M

Novel anti-hepatitis B agents: A focus on telbivudine.

Int J Clin Pract. 2006 Oct;60(10):1295-9.

PubMed ID
16981973 [ View in PubMed
]
Abstract

Although preventable by vaccination, hepatitis B infection is common, affecting more than 350 million individuals worldwide. Chronic hepatitis B infection is associated with the complications of chronic liver disease including cirrhosis and hepatocellular carcinoma. Current agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy and a demand for new agents and strategies continues. This review focuses on telbivudine, a novel agent in the fight against hepatitis B.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
TelbivudineProtein PProteinHBV-F
Yes
Not AvailableDetails